Abemaciclib

FDA label information for this drug is available at DailyMed.

Use in Cancer

Abemaciclib is approved to treat:

• Breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-). It is used:
  • In adults whose cancer has spread. It is used:
    • With fulvestrant in adults whose cancer got worse after treatment with hormone therapy.
    • Alone in adults whose cancer got worse after treatment with hormone therapy and chemotherapy given for metastatic cancer.
    • With an aromatase inhibitor given as first-line hormone therapy in men and postmenopausal women.
  • With tamoxifen citrate or an aromatase inhibitor as adjuvant therapy in adults with early-stage breast cancer that has spread to the lymph nodes and has a high risk of coming back.

Abemaciclib is also being studied in the treatment of other types of cancer.

More About Abemaciclib

Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.

More About Abemaciclib – A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

New Way to Classify Meningioma Brain Tumors Suggests Potential Treatments

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Abemaciclib – Check for trials from NCI’s list of cancer clinical trials now accepting patients.